RecruitingNCT05837221

Microbiome in Head and Neck Squamous Cell Carcinoma

Role of Human Microbiome in Head and Neck Cancer


Sponsor

University of Colorado, Denver

Enrollment

60 participants

Start Date

May 23, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

This study aims to determine whether dysbiosis actively contributes to HNSCC and if so, the underlying molecular mechanisms.


Eligibility

Min Age: 18 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating the relationship between the bacteria and microorganisms living in and around oral squamous cell carcinoma (OSCC) — a type of mouth cancer — and the patient's immune response. Researchers want to understand whether specific microbiome patterns are associated with cancer development, which could help identify new prevention or treatment targets. **You may be eligible if...** - You are 18 or older - You are being seen at the University of Colorado otolaryngology (ear, nose, and throat) clinic - You have been diagnosed with oral squamous cell carcinoma (mouth cancer), OR - You are visiting the same clinic for unrelated reasons and match the age range of a cancer patient (to serve as a comparison) **You may NOT be eligible if...** - You are under 18 or over 100 years old - You are unwilling to participate Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTMetagenomic sequencing

Shotgun metagenomic sequencing will characterize cancer-associated changes in microbial functional capacity and species/strain-level taxonomic profiles. Metagenomics will provide data on microbial functional capacity along with broader taxonomic classifications.

DIAGNOSTIC_TESTMetabolic analysis

Metabolic analysis will be conducted using LC/MS-based metabolic analysis. A targeted approach will quantify a panel of 30 compounds including Trp pathway products while a non-targeted approach, when applied to both lipid and aqueous phase compounds, will profile relative changes in compounds that may influence host


Locations(1)

University of Colorado Cancer Center

Aurora, Colorado, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05837221


Related Trials